Abstract A034: Bayesian adaptive design for phase I drug combination trials

Abstract

Abstract Drug combination therapy is the most commonly used approach to overcome acquired resistance to cancer therapy. Designing phase I drug combination trials faces several challenges beyond the conventional single-agent dose escalation studies, e.g., two-dimensional dose space and partial order in toxicity. In this presentation, we will overview novel Bayesian adaptive designs for drug combination trials. In particularly, we will focus on model-assisted designs that are simply to implement, while yielding superior operating characteristics. Trial example and software will be provided to illustrate the application of the novel designs. Citation Format: Ying Yuan, Suyu Liu. Bayesian adaptive design for phase I drug combination trials [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A034.